Literature DB >> 5499047

Further purification of a polypeptide demonstrating enterogastrone activity.

J C Brown, V Mutt, R A Pederson.   

Abstract

1. The further purification of a polypeptide having potent enterogastrone activity, without CCK-PZ effects, is described.2. The material was inhibitory when doses of 1.0 mug/kg.hr were administered intravenously. Amino acid analyses demonstrated the absence of proline, a high content of glutamine and a preponderance of lysine over arginine. Tryptic degradation destroys the inhibitory effect of the polypeptide. Further studies must be performed before the physiological status of the polypeptide can be ascertained.

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 5499047      PMCID: PMC1396039          DOI: 10.1113/jphysiol.1970.sp009155

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  4 in total

1.  The gastrointestinal hormones, secretin and cholecystokinin-pancreozymin.

Authors:  J E JORPES; V MUTT
Journal:  Ann Intern Med       Date:  1961-09       Impact factor: 25.391

2.  Two-dimensional paper chromatographic systems with high resolving power for amino acids.

Authors:  R R REDFIELD
Journal:  Biochim Biophys Acta       Date:  1953-02

3.  Preparation of highly active enterogastrone.

Authors:  J C Brown; R A Pederson; E Jorpes; V Mutt
Journal:  Can J Physiol Pharmacol       Date:  1969-01       Impact factor: 2.273

4.  The electrophoresis of histones in polyacrylamide gel and their quantitative determination.

Authors:  E W Johns
Journal:  Biochem J       Date:  1967-07       Impact factor: 3.857

  4 in total
  44 in total

1.  Is GIP a glucagon cell constituent?

Authors:  J Alumets; R Håkanson; T O'Dorisio; K Sjölund; F Sundler
Journal:  Histochemistry       Date:  1978-12-13

2.  Gastric inhibitory polypeptide links overnutrition to obesity.

Authors:  A Ballinger
Journal:  Gut       Date:  2003-03       Impact factor: 23.059

Review 3.  Glucagon-like peptide 1 (GLP-1).

Authors:  T D Müller; B Finan; S R Bloom; D D'Alessio; D J Drucker; P R Flatt; A Fritsche; F Gribble; H J Grill; J F Habener; J J Holst; W Langhans; J J Meier; M A Nauck; D Perez-Tilve; A Pocai; F Reimann; D A Sandoval; T W Schwartz; R J Seeley; K Stemmer; M Tang-Christensen; S C Woods; R D DiMarchi; M H Tschöp
Journal:  Mol Metab       Date:  2019-09-30       Impact factor: 7.422

Review 4.  T1R and T2R receptors: the modulation of incretin hormones and potential targets for the treatment of type 2 diabetes mellitus.

Authors:  Cedrick D Dotson; Stephan Vigues; Nanette I Steinle; Steven D Munger
Journal:  Curr Opin Investig Drugs       Date:  2010-04

5.  Hormonal control of gastrointestinal motility.

Authors:  R F Harvey
Journal:  Am J Dig Dis       Date:  1975-06

Review 6.  Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones.

Authors:  Amosy E M'Koma; Paul E Wise; Roberta L Muldoon; David A Schwartz; Mary K Washington; Alan J Herline
Journal:  Int J Colorectal Dis       Date:  2007-06-19       Impact factor: 2.571

7.  Gastric inhibitory polypeptide (GIP). Intestinal distribution and stimulation by amino acids and medium-chain triglycerides.

Authors:  T M O'Dorisio; S Cataland; M Stevenson; E L Mazzaferri
Journal:  Am J Dig Dis       Date:  1976-09

8.  Oral glucose augmentation of insulin secretion. Interactions of gastric inhibitory polypeptide with ambient glucose and insulin levels.

Authors:  D K Andersen; D Elahi; J C Brown; J D Tobin; R Andres
Journal:  J Clin Invest       Date:  1978-07       Impact factor: 14.808

9.  Influence of hemodialysis on incretin hormones and insulin secretion in diabetic and non-diabetic patients.

Authors:  Anna Masajtis-Zagajewska; Ilona Kurnatowska; Małgorzata Wajdlich; Marta Jagodzińska; Michał Nowicki
Journal:  Int Urol Nephrol       Date:  2013-05-14       Impact factor: 2.370

10.  Incretin-based therapies: new treatments for type 2 diabetes in the new millennium.

Authors:  Joan Khoo; Christopher K Rayner; Karen L Jones; Michael Horowitz
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.